https://www.selleckchem.com/pr....oducts/2-deoxy-d-glu
Sitagliptin is a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes (T2D). Limited real-world data on its effectiveness and safety are available from an Italian population. We evaluated long-term clinical data from the single-arm PERsistent Sitagliptin Treatment Outcomes (PERSO) study, which collected information on 440 patients with TD2 (275 men, 165 women; mean age 64.1 years; disease median duration 12 years) treated with sitagliptin 'add-on'. For each patient, we estimated the 10-year cardiova
Me gusta
Comentario
Compartir
